Google
VERU Stock Price & Analysis — Veru Inc (Healthcare >> Biotechnology)
VERU FAQ
What is VERU's P/E ratio?
Veru Inc (VERU) currently trades at a P/E ratio of 24.74.
What is VERU's ROE?
Veru Inc reports a Return on Equity (ROE) of -40.11%.
What is VERU's dividend yield?
Veru Inc offers a dividend yield of 0.00%.
What is VERU's Quality Score?
Our AI rates VERU's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy VERU?
Our AI Timing Score for VERU is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does VERU belong to?
Veru Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
VERU AI Analysis Summary
Our AI summary for VERU: Veru Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 24.74, ROE of -40.11%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.26
Price
0.02
(0.89%)
Day Change
|
|
|---|
VERU, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.26 |
| PBV / Sector |
1.03 / 44,219.29
GREAT
|
| Earning Per Share | -0.88 |
| PE / Sector |
24.74 / 19.28
|
| PEG or PE/Growth / Sector |
-0.65 / 1.23
|
| Average 1M Daily Value |
0.64 M
GREAT
|
| Average 1W Daily Value |
0.41 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:02:20 |
| Symbol | VERU |
| Name | VERU INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 16.05 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 35.95 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2916 North Miami Avenue, Miami, FL, United States, 33127
Phone: 305 509 6897
Website: https://verupharma.com
Sector: Healthcare >> Biotechnology
Description: Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap